Repligen Q1 Revenue Up 15% to $194M, EPS Beats and Raises Guidance
RGEN•Repligen reported Q1 revenue of $194.0 million, up 15% year-over-year, and delivered EPS of $0.48, beating the $0.38 consensus while expanding adjusted operating margin by 160 basis points. The company raised full-year adjusted EPS guidance to $1.97–$2.05 and maintained a 9%–13% organic revenue growth forecast, as Jefferies set a $142 price target (13% upside).
1. Q1 2026 Financial Results
Repligen posted Q1 revenue of $194.0 million, a 15% year-over-year increase driven by 11% organic growth, and reported EPS of $0.48 versus a $0.38 estimate. The company expanded adjusted operating margin by 160 basis points through cost management, pricing execution and a favorable product mix, led by high-margin Analytics.
2. Updated 2026 Guidance
Building on the quarter’s performance, Repligen reaffirmed its full-year organic revenue growth target of 9%–13% and increased its adjusted EPS guidance to a range of $1.97–$2.05. This upward revision underscores management’s confidence in sustained midcycle demand and operational execution.
3. Strategic Initiatives and Margin Expansion
Repligen formed a dedicated Transformation Office to support its ’Fit for Growth’ plan, targeting a 30% adjusted EBITDA margin by 2030 through manufacturing optimization and IT modernization. The company also divested its non-core Polymem business, saw a notable uptick in capital equipment orders in March, and launched a China partnership to bolster local manufacturing competitiveness in 2027.
4. Analyst Outlook
Jefferies set a $142 price target on Repligen shares, implying roughly 13% potential upside from recent levels. The firm's positive outlook reflects confidence in the company’s earnings trajectory and new full-year guidance.
